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33.3% of cases (p  ! 0.001). Subtype specificity was also pres-
ent in hMSH2 staining, where chromophobe RCC retained a 
high expression in 41.7% of cases, while clear cell and papil-
lary tumors did not (29.9 and 23.1%; p = 0.01).  Conclusion: 
MSI and EMAST are rare events in sporadic RCC, whereas di-
minished MMR protein expression is linked to tumor entity 
and might contribute to the different biological behavior of 
the RCC subtypes. 
 
Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Renal cell cancer (RCC) is a genetically heterogeneous 
disease. Molecular biological studies have shown multi-
ple genetic and epigenetic alterations, i.e. subtype-spe-
cific gains and losses of chromosomes, chromosome 
arms and chromosomal regions  [1] . Besides chromosom-
al instability involving alterations in chromosomal seg-
regation and the formation of cells containing fragmen-
tized, deleted or duplicated chromosomes, microsatellite 
instability (MSI) has been described as a distinct type of 
genetic instability  [2, 3] . Microsatellites are mono- to 
pentanucleotide repeats found throughout the genome. 
Usually they are not located at exons or promoter re-
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 Abstract 
 Objectives: We studied the role of minor mismatch repair 
proteins (MMR) human MutL homologue 1 (hMLH1) and hu-
man MutS homologue 2 (hMSH2) in the main subtypes of 
renal cell carcinoma (RCC).  Methods: Expression of MMR 
proteins hMLH1 and hMSH2 were investigated in 166 RCC 
tumors, containing the main subtypes by immunohisto-
chemistry. Furthermore, each tumor was screened for micro-
satellite instability (MSI) using the National Cancer Institute 
consensus panel for hereditary non-polyposis colon carci-
noma as well as for elevated microsatellite alterations at se-
lected tetranucleotide repeats (EMAST) by 10 additional 
markers.  Results: MSI was found only in 2.0% of analyzable 
cases and EMAST was detected only in 1 patient. hMLH1 and 
hMSH2 expression was reduced in 83.7 (118/141) and 51.2% 
(65/127) of cases, respectively, in a subtype-specific manner. 
None of the clear cell RCC tumors retained a high hMLH1 ex-
pression and 92.0% lost hMLH1 completely, while papillary 
and chromophobe RCC preserved the expression in 25.0 and 
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gions. This finding was attributed to their susceptibility 
to transcription errors caused by polymerases which 
might lead to shifts in open reading frames  [4] . Their 
function remains largely unknown, but a possible role in 
evolution, especially when present at coding sequences 
of minor mismatch repair (MMR) proteins, has been dis-
cussed  [5] . MMR proteins are concerned with correcting 
replication errors by means of homologous recombina-
tion  [6, 7] . Error rates are remarkably increased at mono- 
and dinucleotide repeats, as they cause polymerases to 
slip above average  [8] . Hereditary non-polyposis colon 
carcinoma (HNPCC)-associated cancers are well known 
to be caused by mutations in MMR genes – e.g. human 
MutL homologue 1 (hMLH1), human MutS homologue 
2 (hMSH2), human MutS homologue 6 (hMSH6) – lead-
ing to MMR deficiency and impairment of transcription 
error repair  [2] . Meanwhile, a marker panel targeting es-
pecially vulnerable mono- and dinucleotide sequences 
has been defined and is generally used for the detection 
of MSI  [9] . The fact that HNPCC patients occasionally 
develop RCC  [10] incited several examinations of MSI 
and MMR deficiency in RCC tumors and cell lines  [11–
22] , with contradictory results. Studies were based on 
MSI and immunohistochemistry analyses as well as 
on characterization of the hypermethylation status of 
hMLH1 and hMSH2 including DNA sequencing of the 
complete coding region of the two genes, but only one 
recent investigation used the National Cancer Institute 
(NCI) consensus panel  [21] . Moreover, there are no stud-
ies dealing with MSI status and MMR protein expression 
in the same specimens  [11–19] , and merely one study on 
cell lines exists  [20] . Recently, elevated microsatellite al-
terations at selected tetranucleotides (EMAST) have 
been defined as another type of molecular alterations in 
several tumor types  [23–25] . Furthermore, it has been 
shown to be a distinct form of MSI in tumors of the uri-
nary tract  [26, 27] . EMAST is not linked to known MMR 
gene defects  [23] ; however, p53-dependent DNA repair 
mechanisms have been described to be impaired in tu-
mors with EMAST  [24] . To date, there is no study inves-
tigating EMAST and p53 status together in a well-de-
fined cohort of RCC patients. 
 Our study is designed to clarify the incidence of MMR 
deficiency and MSI as defined by the NCI consensus pan-
el and exploring the role of EMAST in view of the three 
main subtypes of RCC.
 Materials and Methods 
 The ethics committee of the University Hospital of Erlangen 
approved the study protocol.
 One hundred and sixty-six tissue samples from RCC patients 
obtained by tumor nephrectomy were retrieved from the archives 
of the Institute of Pathology, University of Regensburg, Regens-
burg, Germany. All tumors were diagnosed according to the 2004 
WHO classification of RCC  [28] and staged according to the tu-
mor-node-metastasis (TNM) system  [29, 30] . Prior institutional 
review board approval was obtained through the participating 
institutions. RCC specimens consisted of 104 clear cell, 33 papil-
lary, 32 chromophobe, 2 spindle cell, 4 undifferentiated, 3 mixed 
clear cell and papillary RCC, 4 oncocytomas and 1 collecting duct 
carcinoma. TNM classifications ranged from T1a to T3b, cN0 to 
pN2, M0 to M1 and tumor stages from I to III (details are given 
in  table 1 ). The mean age of patients was 63.6 years (range 26–91, 
median 76).
 Microdissection and DNA Isolation 
 DNA was extracted as described previously  [31] from manu-
ally microdissected, formalin-fixed, paraffin-embedded normal 
and tumor tissues by means of the High Pure PCR Template Prep-
aration Kit (Roche Diagnostics GmbH, Mannheim, Germany) 
and according to the manufacturer’s instructions.
Table 1.  Characteristics of MSI and EMAST-positive tumors
Case No. Diagnosis MSI Marker with MSI EMAST Marker with EMAST TP53 alu hMLH1 hMSH2
22 sarcomatoid RCC pT3a N0 
M0 G3
MSI-L MFD15/APC – – n.i. negative moderate
77 papillary RCC pT3a N2 M0 
G2
MSI-H BAT40 D2S123 
MFD15/APC
EMAST D9S747 PKY11
D21S1436
– negative negative
138 chromophobe sarcomatoid 
RCC pT3b N2 M0 G3
MSI-L BAT40 – – n.i. negative negative
M SI-L = MSI-low; n.i. = not informative.
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 Microsatellite Analysis 
 Microsatellite analysis was performed on DNA of tumor and 
corresponding normal tissue. We used the NCI consensus panel, 
supplemented by BAT40, to detect mono- and dinucleotide MSI 
 [9] . For assessment of EMAST, we chose eight microsatellite 
markers (Mycl1, D2S443, UT5037, D8S321, D8S348, D9S303, 
D20S82 and D21S1436) from the literature  [21, 23–25] . Addition-
ally, two tetranucleotide markers on chromosome 9 (D9S304, 
D9S747) were investigated to evaluate the frequency of loss of het-
erozygosity (LOH) on chomosome 9 as they showed high sensitiv-
ity in detecting EMAST in a recent bladder cancer study  [26] . For 
investigation of the deletion status of the p53 gene locus on chro-
mosome 17p13.1, the pentanucleotide marker TP53alu was used 
 [32] . All primer sequences were taken from the Genome Database 
(http://www.gdb.org). DNA amplification conditions and the fol-
lowing procedures for separation and visualization of products 
were published previously  [33] . In short, polyacrylamid gel elec-
trophoresis and silver staining were used. Every gel was assessed 
independently by two investigators (C.S. and R.S.). Informative 
cases were scored as allelic loss (LOH) when the intensity of the 
signal for one allele in the tumor was decreased to at least 50% 
relative to the allele of the control. MSI was defined as the appear-
ance of additional bands or band shifts in the tumor. Tumors were 
classified as MSI-high (MSI-H) if two of the six markers ( 1 30%) 
were found to be unstable. If  ! 30% of the investigated markers 
revealed MSI, the tumor was designated as having low-level insta-
bility (MSI-low). LOH was not counted as MSI, but considered as 
a separate group. All analyses were run in duplicate after indepen-
dent polymerase chain reactions to avoid errors produced by pref-
erential amplification of one allele. Cases with non-reproducible 
amplification patterns were excluded from the study due to minor 
DNA quality or low DNA quantity.
 Immunohistochemistry 
 For immunohistochemical analyses, a RCC tumor microarray 
was built of representative areas from formalin-fixed, paraffin-
embedded tumor material as described previously  [34] . The fresh-
ly cut 5-  m sections of the five resulting blocks underwent strict-
ly synchronous treatment throughout all preparatory steps and 
staining procedures. The latter were carried out on a NexES im-
munohistochemistry system (Ventana Medical Systems, Illkirch, 
France), using the iView DAB Detection Kit (Ventana Medical 
Systems). Protein expression of hMLH1 and hMSH2 was evalu-
ated according to immunohistochemistry standard procedures 
with primary monoclonal antibodies anti-MLH1 (13291A, clone 
G168-728, Pharmingen, San Diego, Calif., USA; dilution 1: 20) and 
anti-hMSH2 (clone 2MSH01, Neomarkers, Fremont, Calif., USA; 
dilution 1: 100) and the help of an Amplification Kit (Ventana 
Medical Systems). As a control for MMR protein staining, we used 
colorectal normal tissue, which is known to express MMR pro-
teins. Scoring of immunoreactivity was performed in a way simi-
lar to that of a previously published study  [35] : negative, no posi-
tive nuclei; weak,  ^  20% of nuclei stained positively; moderate, 
 ^  50% of nuclei stained positively; strong,  1 50% of nuclei stained 
positively. For analysis of combined hMLH1 and hMSH2 loss, 
samples of negative and weak expression of the respective protein 
were banded together to a group named ‘loss of expression’ and 
moderate and strong expression samples to a group termed ‘nor-
mal expression’.
 Statistical Analysis 
 Two-sided Fisher’s exact test was used to study the statistical 
association between MSI and immunoreactivity for hMLH1, 
hMSH2 and combined MMR loss. Staining and microsatellite 
analyses were also studied regarding possible associations with 
histopathological characteristics. p values  ! 0.05 were defined sig-
nificant. As the study was of explorative character, no correction 
for multiple testing was applied  [36] . All statistical procedures 
were performed using Statistical Package for the Social Sciences 
(SPSS) 13.0.
 Results 
 Microsatellite analysis using markers of the NCI con-
sensus panel resulted in stable mono- and dinucleotide 
sequences in the majority of all types of renal tumors. 
Merely 2 cases of MSI-low (1.3%) and 1 of MSI-H (0.7%) 
were found in 152 informative cases, respectively, and 
were of International Union against Cancer (UICC) stag-
es III or IV (p = 0.014). Representative examples for MSI 
in these tumors are given in  figure 1 . Testing all tumors 
with regard to the expression of hMLH1 and hMSH2 by 
immunohistochemistry, we found a proportion of tu-
mors displaying reduced expression of one protein and 
also some tumors showing combined loss in a subtype-
specific manner ( fig. 2 ). None of the clear cell RCC tu-
mors retained high hMLH1 expression and 92.0% (80/87) 
lost hMLH1 completely. Papillary and chromophobe 
RCC preserved full protein expression in 25.0 (7/28) and 
33.3% (4/12), while complete loss was displayed in 64.3 
(18/28) and 58.3% (7/12), respectively (p  ! 0.001). Seventy-
five percent of oncocytomas (3/4) also presented hMLH1 
a b c
N T N T N T
 Fig. 1. Representative examples for detected chromosomal aber-
rations in RCC.  a MSI in marker D2S123.  b MSI in EMAST mark-
er PKY11.  c LOH in EMAST marker D21S1436. N = Normal tis-
sue; T = tumor. 
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protein loss. Subtype specificity was also present in 
hMSH2 stainings, where chromophobe RCC retained 
full protein expression in 41.7% (5/12), while clear cell 
and papillary tumors showed high expression only in 29.9 
(23/77) and 23.1% (6/26) of cases, respectively, and com-
plete loss was visible in only 8.3% (1/12) chromophobe, 
54.5% (42/77) clear cell and 61.5% (16/26) papillary cases 
(p = 0.01). Oncocytomas lost hMSH2 expression in 75% 
(3/4) of cases. For hMSH2, there was also an association 
with pT (p = 0.026) and young age at diagnosis ( ! 45 years 
of age; p = 0.029). No further significant associations were 
found. Representative examples for hMLH1 and hMSH2 
deficiency are given in  figure 3 .
 The single MSI-H tumor displayed combined loss of 
both proteins. Although combined loss of hMLH1 and 
hMSH2 was detected in 50.0% (63/126) of cases, no sig-
nificant correlation with MSI status was found. There 
was also no association with histopathological character-
istics. 
 Additionally, we applied EMAST markers to examine 
the frequency of instability at tetranucleotide sites. 
EMAST was present in only 1 of 130 informative cases 
(0.8%;  fig. 1 ). Remarkably, this tumor was of UICC stage 
IV (pT3a N2 M0), demonstrated a loss of hMLH1 and 
hMSH2 protein and was MSI-H. The association with 
N2 was significant (n = 119; p = 0.008). We also per-
formed TP53alu LOH analysis: 3.1% (3/97) of tumors lost 
an allele at this locus. The single EMAST-positive case 
did not demonstrate LOH at TP53alu. Detailed charac-
teristics of MSI and EMAST-positive cases are reviewed 
in  table 1 .
 Analysis also revealed numerous cases with LOH 
(19.8%, 32/162) at the applied markers. Some of them 
were located at chromosomal regions known to get fre-
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 Fig. 2. Loss of hMLH1 and hMSH2 protein expression is subtype specific (p  ! 0.001). CC = Clear cell RCC; pap = papillary RCC; 
CP = chromophobe RCC. hMLH1: clear cell RCC, n = 87; papillary RCC, n = 28; chromophobe RCC, n = 12. hMSH2: clear cell RCC, 
n = 77; papillary RCC, n = 26; chromophobe RCC, n = 12. 
a b
c d
 Fig. 3. Immunohistochemistry of MMR proteins.  a Strong nucle-
ar staining in a hMLH1-positive clear cell RCC.  b Absence of 
staining in a hMLH1 chromophobe RCC.  c Strong nuclear stain-
ing in a hMSH2 clear cell RCC.  d No immunohistochemical 
staining in a hMSH2.   
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quently lost in a subtype-specific manner in RCC, but 
also additional ones were observed: clear cell RCC, that 
are known to display loss of different regions of 3p, 6q, 
8p, 9p and 14q, demonstrated LOH at UT5037 (chromo-
some 8; 1.7%, 1/59), but also at Mycl1 (chromosome 
1p34.1–34.3; 2.6%, 2/78), D8S348 (chromosome 8q24.13–
24.3; 5.4%, 4/74), D8S321 (chromosome 8q24.13–8; 5.75, 
4/70), D9S747 (chromosome 9q32; 3.2%, 2/63), D9S303 
(chromosome 9q21.32; 1.3%, 1/75) and D20S82 (chromo-
some 20p12.3; 1.0%, 1/96). Papillary tumors, that are 
noted for gaining chromosomes displayed LOH at Mycl1 
(8.3%, 2/24), D2S443 (chromosome 2p 13.2–13.1; 5.0%, 
1/20), UT5037 (17.6%, 3/17), D9S747 (5.6%, 1/18), D9S304 
(chromosome 9p21; 4.0%, 1/25) and D9S303 (14.3%, 
3/21). Chromophobe tumors often harboring combined 
losses of chromosomes 1, 2, 6, 10, 13, 17 and 21 were 
found to display LOH at Mycl1 (71.4%, 5/7) and D2S443 
(14.3%, 1/7), but also at D8S348 (20.0%, 2/10) and D9S303 
(10.0%, 1/10). Oncocytomas which are known for loss of 
1p, 14q and Y displayed LOH at D9S303 (1/4) and Mycl 
(2/4).
 Discussion 
 RCC has occasionally been reported to occur in pa-
tients with HNPCC and some RCCs have been shown to 
have MSI at multiple loci. Therefore, separate studies fo-
cused on MSI and MMR deficiency in RCC. Leach and 
colleagues  [20] reported three RCC lines with hMLH1 
deficiency, two of which carried hMLH1 mutations and 
were genetically unstable. They also examined the ex-
pression of hMSH2, hMSH6 and hPMS2; all of them were 
detectable in their 25 cell lines. Deguchi et al.  [12] ana-
lyzed hMLH1, hMSH2, hMSH3, hMSH6, hPMS1 and 
hPMS2 mRNA as well as protein expression in both RCC 
tissues and cell lines and found mRNA loss of hMLH1 
and hMSH3, which did not rise after cell line treatment 
with 5-aza-2  deoxycytidine, suggesting that mechanisms 
other than promoter hypermethylation have to be in-
volved. Similarly, Rubio-del-Campo and coworkers  [21] 
focused on MSI and promoter hypermethylation status 
of the hMLH1 and hMSH2 encoding genes, using the 
Bethesda microsatellite panel for the first time. As a re-
sult, they found loss of function of both hMLH1and 
hMSH2 not to be involved in sporadic RCC, neither by 
promoter methylation nor by mutation in their exons. In-
terestingly, LOH was common among their patients with 
RCC, leading to the conclusion that genomic instability 
in RCC does not affect small fragments of the genome 
(MSI), but is related to the level of large fragments (chro-
mosomes). Loss of 3p for example, or part of it, is a char-
acteristic feature of clear cell RCC  [28] and hMLH1 is 
known to be located on 3p21–23  [37] , which elucidates the 
phenomenon of hMLH1 deficiency in spite of stable nu-
cleotide microsatellites. Loss of hMLH1 and hMSH2 pro-
tein expression regarding the different RCC subtypes was 
observed first by Baiyee and Banner  [38] ; in detail, defi-
ciency in hMLH1 was found in 40% for clear cell (n = 20) 
and in 50% for papillary tumors (n = 8), while hMSH2 
was lost in 20% of their clear cell and none of their papil-
lary RCC specimens. Chromophobe RCCs (n = 4) were 
found to be deficient in hMSH2 but not in hMLH1. In 
contrast, our study – containing 104 clear cell, 33 papil-
lary and 32 chromophobe RCC specimens – noticed loss 
of hMLH1 and hMSH2 much more frequently in all three 
RCC subtypes. The differences were particularly evident 
in clear cell RCC with deficient expression for hMLH1 in 
92% and for hMSH2 in 61.5% of cases. Loss of both 
hMLH1 and hMSH2 was also observed to a greater ex-
tend in papillary and chromophobe RCC cases than de-
scribed by Bayiee and Banner  [38] . However, a potential 
role of hMLH1 and hMSH2 as diagnostic or prognostic 
biomarkers remains uncertain. Apart from a high fre-
quent loss of expression for hMLH1 in clear cell RCC, 
both markers are not sufficient to differentiate clearly 
between any of the three subtypes, and expression of 
hMSH2 – as a potential prognostic marker – is actually 
limited to advanced tumor stage but not related to meta-
static disease. 
 The impact of MSI on RCC was repeatedly assessed in 
the literature. Using the NCI consensus marker panel, we 
detected 2.0% positive cases, confirming former studies 
which also reported a low incidence, i.e. 0–0.04% of MSI 
in RCC  [16, 19] . In contrast, two former studies not using 
the NCI consensus marker panel identified 22.7–25% of 
MSI-positive cases  [13, 39] . Our significant correlation of 
MSI-positive cases and high UICC stage has to be regard-
ed very cautiously, as the number of positive cases was 
low (n = 3) and there was no correction for multiple test-
ing.
 The role of EMAST in tumors currently remains un-
clear and needs further examination  [40] . We did detect 
EMAST in only one tumor (0.8%). Although our group 
has already demonstrated that EMAST and MSI on 
mono- or dinucleotide repeats usually do not overlap, this 
EMAST-positive case was also MSI-H and MMR defi-
cient. However, due to the low incidence of EMAST, our 
finding should be interpreted carefully and rather be 
classified as an accidental result. 
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 Similar to Rubio-del-Campo and colleagues  [21] , we 
also found a high amount of LOH RCC cases, which was 
in accordance with common subtype-specific gains of 
chromosomal regions. Moreover, we detected LOH in ad-
ditional regions that might be more uncommon, espe-
cially concerning clear cell and papillary RCC.
 In summary, our findings support the hypothesis that 
RCC is a genetic instable disease, but not due to either 
type of MSI. Further investigations are required to eluci-
date the pathways of activation and inactivation of MLH-
1 and MSH-2 in terms of malignant transformation and 
whether diminished MMR protein expression might 
contribute to the different biological behavior of the three 
main RCC subtypes. 
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